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Abstract
Aims: To prospectively evaluate the use of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) in the definition of
the treatment response after primary treatment of advanced epithelial ovarian cancer (EOC).
Materials and methods: Forty-nine patients with advanced EOC had an 18F-FDG PET/CT scan before and after primary treatment. The treatment response was
defined with the currently used radiological and serological Response Criteria in Solid Tumors (RECIST1.1/GCIC) criteria and the modified PET Response Criteria
in Solid Tumors (PERCIST). The concordance of the two methods was analysed. If the patient had a complete response to primary treatment by conventional
criteria, the end of treatment 18F-FDG PET/CT scan (etPET/CT) was not opened until retrospectively at the time of disease progression. The ability of etPET/CT to
predict the time to disease recurrence was analysed. The recurrence patterns were observed with an 18F-FDG PET/CT at the first relapse.
Results: The agreement of the RECIST1.1/GCIC and modified PERCIST criteria in defining the primary treatment response in the whole patient cohort was good
(weightedkappacoefficient¼0.78).Of thecomplete responders (n¼28), 34%hadmetabolicallyactive lesionspresent intheetPET/CT,most typically in the lymphnodes.
The same anatomical sites tended to activate at disease relapse, but were seldom the only site of relapse. In patients with widespread intra-abdominal carsinosis at
diagnosis, the definition of metabolic response was challenging due to problems in distinguishing the physiological FDG accumulation in the bowel loops from the
residual tumour in the same area. The presence of metabolically active lesions in the etPET/CT did not predict earlier disease relapse in the complete responders.
Conclusions: In the present study, etPET/CT revealed metabolically active lesions in complete responders after EOC primary therapy, but they were insignificant
for the patient’s prognosis. The current study does not favour routine use of 18F-FDG PET/CT after EOC primary treatment for complete responders.
 2018 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
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Epithelial ovarian cancer (EOC) is usually diagnosed at an
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10.1016/j.clon.2018.04.007platinum/taxane-based chemotherapy are the cornerstones
of treatment. Inwidely spread inoperable cases, the primary
treatment may start with neoadjuvant chemotherapy
(NACT) followed by interval debulking surgery [1,2]. In
addition to the FIGO stage and surgical outcome, the
response to platinum-based chemotherapy is a significant
prognostic factor [3,4]. The response to first-line treatment
is measured with radiological and serological parametersAll rights reserved.
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Table 1
Patient characteristics
Variables Patients (n) %
Total 49 100









Fallopian tube 3 6%
Histology
J. Hynninen et al. / Clinical Oncology xxx (2018) 1e82[5]. A computed tomography (CT) scan is recommended at
the end of first-line chemotherapy to define disease status.
If the serum tumour marker CA125 is increased at the time
of diagnosis, serial CA125 measurements can be useful in
monitoring the treatment response [6]. A complete
response to first-line therapy requires both normalisation of
CA125 during treatment and no signs of residual disease in
CT [5e7].
In clinical trials, an objective evaluation of drug response
is essential. Tumour shrinkage during treatment and the
time of progression are important end points. The Defini-
tions of Objective Endpoints were refined when the World
Health Organization criteria [8], first presented in 1981,
were followed by the Response Criteria in Solid Tumors
(RECIST) criteria in 2000 [9]. These criteria have subse-
quently been widely adopted by academic research groups
and the medical industry for trials where the primary end
points are an objectively measured response to treatment
or disease progression. The updated RECIST 1.1 criteria [7]
published in 2009 clarified some questions and impracti-
calities in the earlier version. In addition, RECIST 1.1 takes
metabolic positron emission tomography (PET) imaging
into account when evaluating disease progression.
Treatment response assessment with PET imaging is not
included in the current generally accepted guidelines. The
PET Response Criteria in Solid Tumors (PERCIST) criteria
[10] were introduced in 2009 in order to unify the quality of
scanning procedures and the evaluation of metabolic
treatment response. The PERCIST categories for response to
treatment (complete metabolic response [CMR], partial
metabolic response [PMR], stable metabolic disease and
progressive metabolic disease) resemble the anatomical
RECIST categories. A recent practical guide [11] has helped
with the implementation of the proposed criteria into
clinical practice. Despite these efforts made to unify meta-
bolic response assessment, a variety of treatment response
methods are currently clinically applied.
The present prospective analysis focuses on treatment
response evaluation at the end of EOC first-line therapy of
advanced EOC. We compared the concordance of the
currently used RECIST1.1/GCIC criteria and the modified
PERCIST criteria. In addition, we evaluated whether an 18F-
fluorodeoxyglucose (18F-FDG) PET/CT scan at the end of
first-line therapy could find prognostic subgroups in pa-
tients with complete response by conventional criteria. We
hypothesised that complete response patients with
increased metabolic activity in the end of treatment 18F-
FDG PET/CT (etPET/CT) scan would have earlier disease
progression.High grade serous 43 88%
Low grade serous 5 10%




Macroscopic residual tumour in surgery
No 13 27%
Yes 36 73%
PDS, primary debulking surgery; NACT, neoadjuvant
chemotherapy.Materials and Methods
Patients
This study was conducted at the Department of Obstetrics
and Gynecology, Turku University Hospital, Finland and was
approved by the local ethics committee (ClinicalTrials.gov
identifier: NCT01276574). All patients with suspectedPlease cite this article in press as: Hynninen J, et al., Clinical Value of 18
mography in Response Evaluation after Primary Treatment of Advanced
10.1016/j.clon.2018.04.007advanced ovarian, fallopian tube or peritoneal cancer were
eligible to participate in this prospective clinical trial. Patients
with diabetes mellitus or a history of previous cancer were
excluded. BetweenOctober2009andMarch2014, 87patients
were recruited. The present analysis consists of 49 patients
with FIGO stage III or IV disease who had an 18F-FDG PET/CT
scan at the time of diagnosis and at the end of first-line
chemotherapy. All the patients received platinum/taxane-
based chemotherapy. Bevacizumab became part of the EOC
first-line treatment during the study period and six patients
received bevacizumab maintenance therapy. The character-
istics of the 49 patients included are presented in Table 1.PET/CT Scanning Procedure and Imaging Analysis
A pretreatment 18F-FDG PET/CT scan from the base of the
skull to mid-thigh was carried out within the 2 weeks
before the PDS/diagnostic laparoscopy. The etPET/CT scan
was scheduled 3e4 weeks after the six cycles of platinum/
taxane chemotherapy in patients who underwent PDS
(n ¼ 22). For the 27 patients who received NACT, the etPET/
CT was taken after a total of six to nine chemotherapy
cycles.
The scanning procedure with whole-body contrast-
enhanced 18F-FDG PET/CT (with 64-row Discovery STE or
VCT; General Electric Medical Systems, Milwaukee, WI,
USA) has been described previously [12]. Briefly, all patients
fasted for 6 h before the intravenous injection of 4 Mbq/kg
18F-18F-FDG. The low-dose PET/CT (kV 120, Smart mA range
10e80) from skull base to mid-thigh was carried out 50e60
min after the tracer injection. It was followed by a whole-
body diagnostic high-dose contrast-enhanced CT scan (kVF-fluorodeoxyglucose Positron Emission Tomography/Computed To-
Epithelial Ovarian Cancer, Clinical Oncology (2018), https://doi.org/
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venous injection of the contrast agent. PET images were
reconstructed with 128  128 matrix size in fully three-
dimensional mode using an ML-OSEM reconstruction al-
gorithm. Imaging analysis was carried out using an ADW4.5
workstation.
Two experienced nuclear medicine physicians analysed
the PET/contrast-enhanced CT images taking into account
physiological FDG accumulation. The baseline scans were
evaluatedwith a detailed systematic assessment of all intra-
abdominal and intrathoracic lesions. All the lesions with
visually abnormal FDG uptake were further evaluated
quantitatively with a determination of maximum stand-
ardised uptake value (SUVmax), and their anatomical
counterparts were defined. Similarly, at the end of treat-
ment, all the metabolically active lesions were also evalu-
ated both visually and quantitatively.
Treatment Response Evaluation after First-line Therapy
At the end of primary treatment, the contrast-enhanced
CT scans were analysed by radiologists who were blind to
the PET/CT scans. The response to primary therapy was
defined with RECIST 1.1/GCIC criteria. Each patient was
categorised as a complete responder, a partial responder or
as having stable disease or disease progression. If the pa-
tient had a partial response or stable/progressive disease,
the etPET/CT scan was opened and used in treatment
planning. In the complete responders, the results of the
etPET/CT were not opened until disease recurrence.
Consequently, the complete responder’s treatment was not
interfered with by any possible metabolic activity in the
etPET/CT scan. The patients were monitored with regular
follow-up visits according to the policy of the hospital.
Afterwards, the treatment response of all the 49 patients
was defined retrospectively from etPET/CT scans with the
modified PERCIST criteria. The etPET/CT findings were
compared with the detailed analyses carried out on the
baseline PET/CT scan. The PERCIST response categories were
used, but instead of SULpeak we calculated the change in
the metabolic activity by using the pre- and post-treatment
SUVmax. The main difference is that SUL (lean body mass-
normalised SUV [SUVlbm]) is less dependent on theTable 2
Epithelial ovarian cancer (EOC) primary treatment response in 49 adva
(RECIST1.1/GCIG) and modified PET Response Criteria in Solid Tumors (P






Complete response 19 10




Spearman correlation ¼ 0.57.
Weighted kappa coefficient ¼ 0.78.
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SUV [13]. A CMR was defined as the visual disappearance of
all metabolically active tumours in the etPET/CT scan. For a
PMR, a decrease of greater than or equal to 30% was war-
ranted between the most intense evaluable lesion at base-
line and the most intense lesion at follow-up (not
necessarily the same lesion). For metabolic progression,
either a 30% increase in SUVmax in the most intense lesion
or a new metabolically active lesion/lesions were needed.
Data Analysis
The association of basic clinical parameters (FIGO stage,
residual tumour in surgery, treatment modality PDS/NACT)
and tumour response defined with modified PERCIST
criteria was analysed with a Spearman correlation and a
chi-squared test. P-values less than 0.05 were considered
significant. The concordance of RECIST1.1 and PERCIST
criteria in the treatment response evaluationwas calculated
by using a Spearman correlation and a quadratic weighted
kappa (ĸ), which measures the level of agreement for cat-
egorical variables [14]. Here, we considered ĸ values above
0.6 as high agreement. The prognostic power of etPET/CT
was evaluated in patients who had a complete response
according to conventional RECIST1.1/GCIC response criteria.
The patients with increased activity in etPET/CT were
compared with patients with a negative PET/CT scan: the
time from the etPET/CT to progression was calculated and
KaplaneMeier models were made. Data analyses were
carried out in R version 3.3.3 [15].Results
The treatment responses of the 49 patients measured
with conventional RECIST1.1/GCIC criteria and with meta-
bolic imaging are presented in Table 2. The agreement of the
RECIST1.1/GCIC and modified PERCIST criteria was sub-
stantial (ĸ ¼ 0.78). The dispersion was greatest with the
RECIST1.1/GCIC partial responders (n ¼ 15): 53% also had a
PMR, whereas 33% had a CMR and 14% either stable or
progressive metabolic disease. The reason for partial
response by conventional criteria was residual disease in CTnced EOC patients defined with Response Criteria in Solid Tumors
ERCIST) criteria. The grey boxes indicate the number of cases where
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both in four cases. In the six patients who received bev-
acizumab, the conventional and metabolic responses were
quite concordant (six complete response/CMR and one
complete response/PMR) and they were included in the
analyses.
Increased metabolic activity detected in etPET/CT was
not associated with the FIGO stage (III versus IV) (P ¼ 0.32),
residual tumour in surgery (P ¼ 0.62) or the choice of pri-
mary treatment strategy (PDS versus NACT) (P ¼ 0.09).
Forty-three of the 49 patients responded to the first-line
therapy, 29 with a complete response and 14 with a partial
response. The conventional RECIST1.1/GCIC criteria pre-
dicted the time to disease recurrence (P < 0.05) (Figure 1a).
Themedian time from etPET/CT to progressionwas 5.8 (95%
confidence interval 3.4e11.0) months in partial and 13.8
(95% confidence interval 10.8e26.1) months in complete
responders. The partial responders relapsed earlier, even
though half of them received extra chemotherapy cycles
after the response evaluation scan.The etPET/CT Findings of the Complete RECIST1.1/GCIC
Responders
Twenty-nine of the 49 patients had a complete response
to primary therapy according to RECIST1.1/GCIC criteria.
Fifteen patients were treated with PDS and 14 with NACT;
12 had no residual tumour in surgery. Of the 29 patients,
34% (10/29) had residual metabolic activity in etPET/CT
(Table 3). In seven patients, the metabolically active lymph
nodes were the only abnormal finding in the etPET/CT. In six
cases, the same lymph nodes were active at the time of
diagnosis and remained active in the etPET/CT scan. In one
case, when re-evaluated retrospectively, the mediastinal
FDG activity in the etPET/CT was considered inflammatory.
Three complete responders were considered to haveTable 3
The positron emission tomography/computed tomography (PET/CT) fin













5 Parailiacal lymph node Yes
6 Intra-abdominal Yes
7 SdLN Yes






SdLN, supradiaphragmatic lymph node.
* Multiple active lesions.
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When the etPET/CT scans were compared with the pro-
gression PET/CTs, two patients were found to have probable
false-positive findings on etPET/CT: one had physiological
activation near the bowel loops (Figure 2a) and another had
metabolic activity in the diaphragm due to an earlier
pleurodesis.
A follow-up PET/CT scan at the first disease relapse was
available in eight of 10 complete responders (Table 3). Six
patients had disease activation detected in the same
anatomical site that had showed activity in the etPET/CT. In
addition, most patients had several new active lesions
(Figure 2b). In one patient, who had disease progression 18
months after etPET/CT, the cardiophrenic lymph node
metastasis, which was also active in etPET/CT, was the only
site of recurrence.
The Prognostic Value of Metabolic Activity in etPET/CT in
Complete Responders
The prognostic value of residual metabolic activity in the
etPET/CT was only analysed for the RECIST1.1/GCIC com-
plete responders, whose etPET/CT was not opened until
recurrence occurred, and who received no extra chemo-
therapy after the etPET/CT scan. One non-blinded case was
removed from survival analysis (remaining n ¼ 28). The
residual metabolic activity detected in the etPET/CT did not
predict the time to progression in RECIST1.1/GCIC complete
responders (Figure 1b).Discussion
Imaging of ovarian cancer is challenging due to the
typical spread pattern to the adjacent organs and around
the peritoneal cavity. 18F-FDG PET/CT is useful in EOC
staging [12,16,17] and in detecting disease relapse [18], butdings of the 10 patients who had a complete response to primary
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Fig 1. The KaplaneMeier curves present the time from the end of treatment positron emission tomography/computed tomography (etPET/CT) to
disease progression: (a) in the first-line therapy responders stratified by Response Criteria in Solid Tumors (RECIST1.1/GCIC) criteria (P < 0.05);
(b) in patients with complete response according to RECIST1.1/GCIC criteria, stratified by metabolic response according to PET Response Criteria
in Solid Tumors (PERCIST) criteria (P ¼ 0.93).
J. Hynninen et al. / Clinical Oncology xxx (2018) 1e8 5the benefit of treatment response monitoring has not been
shown [19]. 18F-FDG PET/CT is a widely used metabolic
imaging modality in cancer patients in response. In clinical
practice, although patients wish to be monitored with the
most effective imaging method [20], the referring physi-
cians have expressed concerns regarding the possible over
interpretation of the findings [21]. In the current study, 34%
of patients with a complete response after EOC first-line
therapy according to traditional RECIST1.1/GCIC criteria
showed increased metabolic activity in an etPET/CT. Their
disease, however, did not progress earlier than in patients
with a negative etPET/CT. Therefore, we do not recommend
routine response evaluation with 18F-FDG PET/CT after EOC
primary therapy.
The RECIST and PERCIST criteria have shown considerable
difference in the treatment response assessment. In a pooled
analysis of 268 patients with different cancers [22], the
estimated overall response rates were significantly different
between the two criteria (35.1% by RECIST versus 54.1% by
PERCIST, P < 0.05). To our knowledge, there are no previous
studies on the metabolic response according to the PERCIST
criteria in ovarian cancer. In the present study, the overall
agreement of the conventional RECIST1.1/GCIC criteria and
modified PERCIST criteria was good (Table 2). The rate of
CMRwas lower when compared with the anatomical/CA125
response. This may lead to additional chemotherapy cycles
being given to patients based on PET/CT.
In our study, the results of etPET/CT of the RECIST1.1/GCIC
complete responders were not available when the patient’s
further treatment was planned and, therefore, the study
protocol enabled an evaluation of the prognostic power of
etPET/CT. When the etPET/CT scans were opened at the time
of the disease recurrence, small active lesions not visible in
the conventional CT were found in 34% of the complete re-
sponders. The pathological 18F-FDG uptake in etPET/CT,
however, failed to predict the time to disease recurrence
(Figure 1b). There are two possible explanations. First, an
over interpretation of the inflammatory or physiological 18F-
FDG accumulation as cancerous lesions is possible [23].Please cite this article in press as: Hynninen J, et al., Clinical Value of 18
mography in Response Evaluation after Primary Treatment of Advanced
10.1016/j.clon.2018.04.007Accumulation of 18F-FDG near the bowel loops in etPET/CT is
especially challenging [23]. Physiological bowel uptake is a
common finding, which can complicate the interpretation of
the metabolic response of the preoperatively detected
tumour in the same anatomic area (Figure 2a). An alternative
explanation for the negative prognostic effect is that in the
current study, the most common pathological findings in
etPET/CT were metabolically active lymph nodes. Most
complete response/PMR patients had metabolically active
lymph nodes in the corresponding anatomical sites after
primary treatment and at disease relapse. This indicates that
themetabolically active lesions in etPET/CTweremore likely
true metastasis than over interpretation. The significance of
18F-FDG accumulation in the lymph nodes during the course
of EOC treatment needs further clarification and will be the
subject of our next study.
Earlier, second look surgeries were carried out after the
completion of first-line treatment to assess the treatment
response and the intraperitoneal status. At that time, the 18F-
FDG PET/CT findings after the completion of primary therapy
could be histologically verified [24]. In the study by Kim et al.
[25], 18F-FDG PET/CT, after the completion of primary ther-
apy, had a similar prognostic value as the second look sur-
gery. Thesefindings arenot in conflictwithour current result.
The practice of second look surgeries was discontinued, as
the impact on survival could not be shown [26]. The predic-
tive power of etPET/CTon progression-free survival based on
a comparison with second look surgeries remains obscure.
The strength of our study is the careful evaluation of a
prospectively collected cohort of advanced EOC patients.
The scanning protocol was standardised: identical patient
preparation and the same scanner was used in the pre-
treatment and end of treatment scans. The unique pro-
spective study design, where the etPET/CT scan was not
opened in the RECIST1.1/CGIG complete responders, made it
possible to observe these patients without the etPET/CT
result affecting the further treatment.
There were some limitations in the current study setting,
such as the size of the patient cohort being limited. InF-fluorodeoxyglucose Positron Emission Tomography/Computed To-
Epithelial Ovarian Cancer, Clinical Oncology (2018), https://doi.org/
Fig 2. (a) An example of a patient with a probable false-positive finding in end of treatment positron emission tomography/computed to-
mography (etPET/CT). In the pretreatment scan, widespread epithelial ovarian cancer with typical ‘omental cake’ is present. After PDS there was
residual tumour left with a carsinosis seeding on the subdiaphragmal peritoneal surface. The patient reached a complete response to primary
therapy according to Response Criteria in Solid Tumors (RECIST/GCIC) criteria. In etPET/CT, the enhanced metabolic activity was measured in the
mesenterium of the small intestine and near the caecum and was interpreted as a probable active disease. The disease relapsed later after 20
months of follow-up with multiple lesions on the peritoneal surfaces, lig falciforme and liver surface, but not in the caecum. (b) A 61-year-old
patient with widespread disease was treated with neoadjuvant chemotherapy. In interval debulking surgery, a thin residual tumour seeding
remained on the subdiaphragmal peritoneal surface and on small bowel mesentery. After primary therapy, a complete response was reached
according to the RECIST/GCIC criteria. In etPET/CT, the only metabolically active lesion was seen on the peritoneal surface between the liver and
diaphragm (fused transaxial PET/CT scan, bottom line). Relapse occurred after only 4 months with multiple intra-abdominal lesions.
J. Hynninen et al. / Clinical Oncology xxx (2018) 1e86addition, the 18F-FDG PET/CT was compared with a combi-
nation of a CT scan and serological CA125 response, instead
of comparing the two imaging methods, CT and PET/CT.
However, this was the most reliable way to evaluate the
additive value of 18F-PET/CT with regards to the currently
used methods.Please cite this article in press as: Hynninen J, et al., Clinical Value of 18
mography in Response Evaluation after Primary Treatment of Advanced
10.1016/j.clon.2018.04.007If 18F-FDG PET/CT is used in the monitoring of EOC first-
line treatment outside clinical trials, several matters
should be considered. The current guidelines on 18F-FDG
PET/CT imaging are focused on standardising the scanning
protocols [27,28], whereas uniform principles on how to
measure and interpret metabolic changes duringF-fluorodeoxyglucose Positron Emission Tomography/Computed To-
Epithelial Ovarian Cancer, Clinical Oncology (2018), https://doi.org/
J. Hynninen et al. / Clinical Oncology xxx (2018) 1e8 7chemotherapy do not exist. In order to carry out a quan-
titative assessment of metabolic tumour response between
the baseline and follow-up studies, identical patient
preparation and the same scanner with comparable
injected doses of FDG and uptake times should be used. In
addition, the imaging results should be reported in a
manner that the clinician can understand the meaning of
the abnormal findings and the comparability of the
consecutive scans [29].
In order to gain prognostic information from imaging, an
18F-FDG PET/CT scan taken earlier during the cancer therapy
may perform better. EOC first-line therapy consists of sur-
gery and chemotherapy. Response evaluation with imaging
or CA125 cannot distinguish between the effects of the two
treatments. During neoadjuvant treatment, where the
metabolic changes are dependent on chemotherapy alone,
response evolution with 18F-FDG PET/CT has shown some
promising results. The PERCIST criteria were valuable in
neoadjuvant therapy on rectal cancer, where an SUVpeak
decrease predicted a pathological response [30]. Addition-
ally, in oesophageal cancer, PERCIST, in contrary to RECIST,
predicted disease outcome [31]. In ovarian cancer, an early
metabolic response during NACT predicts patient outcome
[32] and the histopathological response in the omentum
[33].
In conclusion, based on the present study, residual
metabolic activity at the end of treatment does not predict
earlier disease relapse. This observation should be validated
in larger trials. The PET-positive areas in etPET/CT tend to
re-activate in disease recurrence, in many cases together
withmultiple new active lesions. The routine use of 18F-FDG
PET/CT offers no extra benefit to those patients who have a
complete response after EOC primary treatment.
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